In wet granulation of high-dose, poorly compressible BCS II active pharmaceutical ingredients, 2-pyrrolidone is incorporated at 5–15% w/w of the granulating fluid to dissolve povidone K30 or copovidone and to form a slow-evaporating binder bridge across primary particles. The granulating fluid is introduced into a high-shear mixer with impeller tip speed 4–8 m/s and side chopper speed 1,500–3,000 rpm; end point is accepted only when impeller torque or power draw rises 15–25% above the dry-mix baseline. Because the boiling point of 2-pyrrolidone is 245 °C and its vapor pressure is substantially lower than water, the wet mass does not surface-dry during extended granulation, which reduces large granule fragmentation but also shifts the residual solvent burden to the drying step. Production drying is performed in a fluid-bed processor with inlet air temperature 55–65 °C and product temperature 35–45 °C until loss on drying reaches 1.5–2.5% w/w; however, 2-pyrrolidone is not removed to below process capability at this stage. A subsequent static tray drying step under vacuum at 25–35 kPa and 50–60 °C for 4–8 h is required to reduce residual solvent. Batch records often show residual 2-pyrrolidone plateaus above 0.1% w/w if the granulate bed is not milled before the vacuum step; therefore, an oscillator or cone mill fitted with a 1.0–1.5 mm screen is used before final drying. Tablet compression of the resulting granulate is performed on a rotary tablet press with precompression 5–8 kN and main compression 15–25 kN for tablets in the 300–500 mg mass range; tablets are accepted when hardness is 80–150 N, friability is ≤0.8% after 100 rotations per USP <1216>, and disintegration per USP <701> completes within 15 min for immediate-release film-coated tablets. The residual solvent specification must be justified because 2-pyrrolidone is not assigned a harmonized PDE in ICH Q3C; a marketing authorization file must therefore carry a tox-qualified in-house limit under the residual solvent framework. The granulation fluid is not suitable for effervescent compositions, because the hygroscopic character of 2-pyrrolidone raises moisture sensitivity and the low evaporation rate compresses drying capacity.

Liquid-Filled Hard Capsule Fill Solvent and Shell Compatibility Limits

For liquid-filled hard capsules, 2-pyrrolidone is used as a co-solvent in fill formulations at 10–25% w/w in combination with PEG 400, propylene glycol, medium-chain triglycerides, or glycerol monooleate. The function is to maintain the active pharmaceutical ingredient in molecular dispersion during capsule shell penetration and disintegration, while the high boiling point prevents rapid evaporation from the fill dosing nozzle. Capsule filling machines operating with positive displacement pistons at 30–45 °C require fill viscosity in the range 100–1,000 mPa·s to avoid splashing and ensure fill weight variability below ±3% RSD. At 2-pyrrolidone concentrations above 20% w/w, gelatin shell softening is observed due to plasticization; hypromellose shells show less deformation but may exhibit retarded dissolution if the fill contains more than 15% w/w water. Band sealing is performed with a gelatin solution at 55–60 °C, and filled capsules are tested for leakage under vacuum at −50 kPa for 5 min. Dissolution testing per USP <711> uses 900 mL of pH 1.2 hydrochloric acid or pH 6.8 phosphate buffer at 37 ± 0.5 °C with paddle speed 50 rpm; samples are analyzed by HPLC with UV detection. When the fill contains 2-pyrrolidone, the dissolution medium may show a transient co-solvent effect that increases the apparent release rate for poorly water-soluble actives; this effect must be distinguished from true dissolution by using a precipitation-inhibiting surfactant in the medium only if specified in the monograph. Batch-to-batch variation in gelatin shell moisture, usually 13–16% w/w, interacts with fill hygroscopicity; dry-shell capsules with moisture below 12% w/w become brittle during banding. Production batches therefore require storage of empty capsules at 20–25 °C and 40–50% RH for at least 24 h before filling. Terminal products include lipid-soluble vitamins, poorly soluble cardiovascular actives, and BCS II weak bases that are degraded in conventional aqueous granulation.

Extrusion-spheronization of poorly soluble actives into multiparticulate granules requires a wetting phase that remains plastic during the residence time in the extruder barrel; a binder phase containing 2-pyrrolidone at 3–10% w/w of the dry powder mass is added to microcrystalline cellulose, lactose monohydrate, and the active. The wet mass is processed through a twin-screw extruder with a length-to-diameter ratio of 25:1, screw speed 100–200 rpm, and die plate aperture 0.8–1.2 mm. The extrudate is transferred to a spheronizer run at 800–1,200 rpm for 2–5 min until spheroid aspect ratio falls below 1.2. The low vapor pressure of 2-pyrrolidone prevents evaporative cooling and surface crusting, but it also means that the spheroids retain solvent after a standard fluid-bed drying step at 50–60 °C for 20–30 min. A vacuum drying stage at 10–20 kPa and 45–55 °C for 4–6 h is required to bring residual 2-pyrrolidone below the internal release threshold. Drying curves typically exhibit a biphasic pattern: free water is removed rapidly, followed by a slow desorption phase controlled by granule pore structure; milling through a 0.8 mm screen before the vacuum stage shortens the second phase. The resulting pellets are filled into hard gelatin capsules or sealed into sachets for reconstitution. Dissolution testing per USP <711> is used with a pH 6.8 buffer and 50 rpm basket or paddle; enteric-coated pellets require an acid stage at pH 1.2 for 2 h followed by buffer stage at pH 6.8. Loss on drying per USP <921> is controlled to ≤1.5% w/w for capsule-filled pellets. Trace elemental impurities are controlled per ICH Q3D; the supplier must provide a risk assessment covering Class 1, 2A, and 2B elements, and oral dosage acceptance limits are calculated from the permitted daily exposure and daily dose. Pellets produced with 2-pyrrolidone are not recommended for highly water-soluble actives that undergo solvent-mediated particle growth in the wet mass, because the prolonged liquid residence creates a recrystallization path; dry granulation or direct compression is preferable for such actives.

How Does 2-Pyrrolidone Function in Injectable Co-Solvent Systems for Poorly Water-Soluble APIs?

In parenteral vehicles, 2-pyrrolidone is evaluated as a co-solvent at 10–40% v/v in purified water-for-injection together with propylene glycol, PEG 400, or mannitol as tonicity agent. The co-solvent effect raises the saturation solubility of poorly water-soluble neutral APIs, while the high dielectric constant of the medium reduces ion-pair formation in glass vials. Terminal sterilization is performed by autoclaving at 121 °C for 15 min; formulations should be screened for hydrolytic degradation of 2-pyrrolidone at pH values below 3.0 or above 9.0. The pH of the final admixture is adjusted to 5.5–7.0 with 0.1 N hydrochloric acid or sodium hydroxide, and osmolality is adjusted to 280–320 mOsm/kg with mannitol or sodium chloride. Filtration through a 0.22 µm sterilizing-grade polyvinylidene fluoride membrane is performed at 20–25 °C under differential pressure below 1.0 bar; flux is inversely related to viscosity, and batches with 2-pyrrolidone at 40% v/v may display viscosity values that require filter area scaling of 1.5–2.0× relative to aqueous solutions. Particulate matter is controlled per USP <788>: for small-volume injectables, light obscuration counts must not exceed 6,000 particles ≥10 µm and 600 particles ≥25 µm per container. Endotoxin content is controlled per USP <85> using a validated limulus amebocyte lysate test with a limit derived from the maximum bolus dose; the solvent supplier must provide a certificate stating endotoxin below the method threshold. The terminal product is packed in Type I borosilicate glass ampoules or vials with butyl rubber stoppers and is administered by intramuscular or slow intravenous injection. Because dilution of the co-solvent in plasma causes a sharp drop in solubility, in-vitro precipitation testing is performed by mixing the formulation with simulated plasma at 37 °C under agitation at 100 rpm; the resulting particle size is measured by dynamic light scattering, and precipitation below 250 nm is regarded as a pass indicator for injectable screening. Published data for specific 2-pyrrolidone-containing injectable formulations is limited; preformulation work should therefore include free fraction studies because solvent binding can shift the apparent log P of the active.

When 2-Pyrrolidone Replaces Ethanol in Soft Gelatin Capsule Fill Media

Soft gelatin capsule fill formulations that contain ethanol often require explosion-proof processing and can produce shell embrittlement through rapid moisture loss; when 2-pyrrolidone replaces ethanol at 5–20% w/w of the fill mass, the fill remains liquid at die roll temperature and the shell moisture balance is more stable. Fill mixtures typically combine 2-pyrrolidone with PEG 400, propylene glycol, and polyvinylpyrrolidone K17 or K30; the active is dissolved at 40–60 °C under nitrogen to prevent oxidative degradation of oxygen-sensitive APIs. The fill mass is deaerated under vacuum at −80 kPa for 30–60 min, and the bubble-free liquid is pumped to a rotary die encapsulation machine with spreader boxes held at 40–50 °C. Gelatin ribbon thickness is controlled at 0.8–1.0 mm; ribbon moisture is measured by near-infrared at 30–40% w/w before die roll sealing. Because 2-pyrrolidone has strong hydrogen-bonding capacity, fill-shell interaction favors migration of water from the shell to the fill, which can increase shell brittleness if the fill water activity is below 0.2; therefore, fill formulations are conditioned to a water activity of 0.45–0.65 before encapsulation. Drying of softgel capsules is performed in a tumble dryer at 20–25 °C and 20–30% RH for 12–24 h, followed by a final tray drying stage until shell loss on drying reaches 6–10% w/w per USP <731>. The terminal product is a sealed soft gelatin capsule for oral use; dissolution testing per USP <711> employs the paddle method at 50 rpm in 900 mL of 0.1 N hydrochloric acid containing 0.5% w/v sodium lauryl sulfate if justified by sink conditions. Visual leakage is evaluated by pressing capsules between filter paper for 24 h at 40 °C and 75% RH; a pass requires no oily halo. The main process constraint is that 2-pyrrolidone cannot be used above 20% w/w in highly filled softgels intended for storage in PVC blisters, because the solvent can migrate into the PVC film and alter the sealing lacquer.

Oral solution and reconstituted suspension vehicles containing 2-pyrrolidone at 2–10% w/v are used as a solubilizing fraction in sugar-free or alcohol-free pediatric and geriatric formulations. The solvent is mixed with purified water, sorbitol, glycerol, and sodium benzoate at 0.1–0.2% w/v; pH is adjusted to 4.5–6.0 with citric acid or sodium citrate. The manufacturing sequence includes heating the solvent phase to 40–50 °C to dissolve the active, then cooling to 20–25 °C before mixing with the aqueous preservative phase to avoid local precipitation. The solution is filtered through a 5 µm clarification filter and filled into amber Type III glass bottles with child-resistant closures. Terminal heating is avoided for heat-labile actives; when required, the solution is pasteurized at 80 °C for 30 min. The main stability risk is chemical degradation of the solvent under strongly acidic or basic conditions; amide ring opening is promoted below pH 3.0 and above pH 9.0, so a buffered pH range is mandatory. Reconstitution of dry powder for oral solution using 2-pyrrolidone-containing diluent is performed at 25–30 °C with manual shaking for 15–30 s; the resulting preparation should pass a 0.5 mm sieve according to the pharmacopeial monograph. Microbiological quality is controlled per USP <51> antimicrobial effectiveness testing or Ph. Eur. 5.1.3, and a preservative efficacy test is required if the formulation is multi-dose. The terminal product is an alcohol-free oral solution or reconstituted suspension intended for dose-flexible administration.